| Category | Finding | Evidence type | Key quantitative details | Key source / URL |
|---|---|---|---|---|
| Identity / verification | **Human UBA7** (UniProt **P41226**) is the **ubiquitin-like modifier-activating enzyme 7**, also called **UBE1L**; it is the **E1 enzyme of the ISG15 conjugation (ISGylation) pathway**. Reviews and primary papers consistently use the human names **UBA7/UBE1L** for the ISG15 E1. (pqac-00000006, pqac-00000009, pqac-00000018) | Structure, review, cell | Madaan 2024 explicitly states UBA7/UBE1L is the **only ISG15-activating enzyme identified to date**. (pqac-00000018) | Afsar et al., 2023-08, *Nat Commun*, https://doi.org/10.1038/s41467-023-39780-z; Sarkar et al., 2023-12, *Trends Microbiol*, https://doi.org/10.1016/j.tim.2023.07.006; Madaan et al., 2024-09, *J Biol Chem*, https://doi.org/10.1016/j.jbc.2024.107686 |
| Core biochemical function | UBA7 catalyzes the canonical **E1 two-step activation reaction for ISG15**: **(1) ATP-dependent adenylation** of the ISG15 C-terminus, **(2) formation of an E1\~ISG15 thioester** on the catalytic cysteine, then **(3) transthiolation to the E2 UBE2L6/UbcH8**. (pqac-00000001, pqac-00000005, pqac-00000006) | Structure, biochemistry | Afsar 2023 reports complexes with **ISG15 adenylate** and **ISG15 thioester** intermediates; Wallace 2023 reports charging assays with timepoints **0, 15, 30, 60, 300, 900 s** and example in vitro conditions including **2.5 µM UBE1L + 3 µM ISG15** for E1 charging and **0.25 µM UBE1L + 2 µM UBE2L6 + 5 µM ISG15** in multi-turnover assays at **25 °C**. (pqac-00000002, pqac-00000005, pqac-00000006) | Afsar et al., 2023-08, https://doi.org/10.1038/s41467-023-39780-z; Wallace et al., 2023-12, https://doi.org/10.1038/s41467-023-43711-3 |
| Enzymatic step 1: adenylation | UBA7 recognizes mature ISG15 and catalyzes **adenylation of its C-terminal glycine motif**, preparing ISG15 for thioester formation. The **ISG15 C-terminal ubiquitin-like domain** is especially important in this step. (pqac-00000001, pqac-00000002, pqac-00000011) | Structure, biochemistry, review | Wallace 2023 used viral effectors to validate that the **ISG15 C-terminal Ubl domain** and **last six C-terminal residues** are important for adenylation. (pqac-00000001, pqac-00000002) | Wallace et al., 2023-12, https://doi.org/10.1038/s41467-023-43711-3; Álvarez et al., 2024-02, https://doi.org/10.3390/vaccines12020153 |
| Enzymatic step 2: E1\~ISG15 thioester | After adenylation, UBA7 forms a **high-energy thioester intermediate** with ISG15 at its catalytic cysteine. This is the activated E1 intermediate used for E2 transfer. (pqac-00000005, pqac-00000006) | Structure, biochemistry | Afsar 2023 modeled transfer intermediates by crosslinking **Uba7 Cys599** to engineered UBE2L6–ISG15; Wallace 2023 trapped UBE1L with **Cys599Ala** in structural work. (pqac-00000001, pqac-00000006) | Afsar et al., 2023-08, https://doi.org/10.1038/s41467-023-39780-z; Wallace et al., 2023-12, https://doi.org/10.1038/s41467-023-43711-3 |
| Enzymatic step 3: transfer to E2 | UBA7 transfers ISG15 from the E1 thioester to the **cognate E2 enzyme UBE2L6/UbcH8**, producing **UBE2L6\~ISG15**, which then functions with E3 ligases for substrate ISGylation. (pqac-00000001, pqac-00000005, pqac-00000006) | Structure, biochemistry | Wallace 2023 captured a **3.45 Å cryo-EM** structure of a chemically trapped **UBE1L–UBE2L6–activated ISG15** complex. (pqac-00000001) | Wallace et al., 2023-12, https://doi.org/10.1038/s41467-023-43711-3 |
| Substrate specificity: modifier | Current evidence supports UBA7 as a **dedicated ISG15 E1**, distinct from the ubiquitin E1 **UBA1**. UBA7 is generally treated as **ISG15-specific**, whereas ubiquitin charging is performed by UBA1 in parallel assays. (pqac-00000003, pqac-00000005, pqac-00000018) | Cell, biochemistry | Clancy 2023 describes UBA7 as the **ISG15-specific E1**; Madaan 2024 states it is the **only known ISG15-activating enzyme**. (pqac-00000003, pqac-00000018) | Clancy et al., 2023-07, https://doi.org/10.1042/bcj20230301; Madaan et al., 2024-09, https://doi.org/10.1016/j.jbc.2024.107686 |
| Specificity determinants vs ubiquitin pathway | Structural and biochemical work indicates fidelity is enforced by **specific UBA7–ISG15 and UBA7–UBE2L6 interfaces**. The **ISG15 C-lobe** makes an extensive side-chain interaction network with the UBA7 adenylation domain; the **ISG15 N-lobe is dispensable** for E1/E2 thioester formation; and the **ISG15 Thr125 patch** helps prevent mis-activation by **UBA1**, sharpening pathway specificity. (pqac-00000002, pqac-00000006) | Structure, biochemistry | Wallace 2023 reports that engineered **ISG15 and UBE2L6 mutants** altered selectivity between the **ISG15 and ubiquitin** pathways. (pqac-00000001, pqac-00000002) | Wallace et al., 2023-12, https://doi.org/10.1038/s41467-023-43711-3; Afsar et al., 2023-08, https://doi.org/10.1038/s41467-023-39780-z |
| Key partners: E2 | The principal cognate E2 is **UBE2L6** (also **UbcH8/UBCH8**). It is the E2 used in structural, biochemical, and cell-based studies of UBA7-mediated ISG15 transfer. (pqac-00000001, pqac-00000005, pqac-00000007) | Structure, biochemistry, review | UBE2L6 charging defects were measurable in time-course assays; specific UBE2 mutations significantly reduced **E2\~ISG15** thioester formation. (pqac-00000002) | Wallace et al., 2023-12, https://doi.org/10.1038/s41467-023-43711-3; Yuan et al., 2023-01, https://doi.org/10.3390/molecules28031337 |
| Key partners: E3 ligases | Reported ISG15 E3 ligases downstream of UBA7 include **HERC5** (dominant human E3), **TRIM25/EFP**, and **ARIH1**. HERC5 is emphasized as the major human E3 and mediates ISGylation of newly synthesized proteins. (pqac-00000008, pqac-00000009, pqac-00000011) | Review, biochemistry | HERC5 is described as the dominant human E3 because loss of HERC5 markedly reduces observable ISGylation; ARIH1 can mono-ISGylate **cGAS** on **K187** in review discussion. (pqac-00000008, pqac-00000011) | Sarkar et al., 2023-12, https://doi.org/10.1016/j.tim.2023.07.006; Álvarez et al., 2024-02, https://doi.org/10.3390/vaccines12020153 |
| Pathway context | UBA7 functions in the **ISGylation / type I interferon innate immune pathway**, acting upstream of ISG15 conjugation to host and viral proteins. ISGylation is reversible, with **USP18** as the major human deISGylase. (pqac-00000009, pqac-00000010, pqac-00000011) | Review | Type I IFN signaling through **IFNAR1/IFNAR2 → JAK/STAT → ISGF3** induces ISGs including ISG15 and its conjugation machinery. (pqac-00000010) | Sarkar et al., 2023-12, https://doi.org/10.1016/j.tim.2023.07.006; Álvarez et al., 2024-02, https://doi.org/10.3390/vaccines12020153 |
| Regulation by interferon | UBA7 is an **interferon-responsive** component of the ISGylation machinery, induced with ISG15, UBE2L6, and E3 ligases during type I IFN responses. (pqac-00000003, pqac-00000010, pqac-00000012) | Cell, review | Reviews describe strong induction of ISG15 system genes by **type I IFN (IFN-α/β)**; Clancy 2023 experimentally examined IFN responses across multiple cell lines. (pqac-00000003, pqac-00000010, pqac-00000017) | Clancy et al., 2023-07, https://doi.org/10.1042/bcj20230301; Bonacci & Emanuele, 2025-07, https://doi.org/10.1042/bst20240859 |
| Regulation by USP18 / cell context | In some human cell contexts, **USP18 suppresses UBA7 expression** despite interferon stimulation. In **HCT116** cells, early USP18 expression was sufficient to suppress the **ISG15 E1 enzyme UBA7**; **USP18 depletion restored interferon-dependent UBA7 and UBCH8 expression** and rescued ISGylation. (pqac-00000003, pqac-00000017) | Cell | Study surveyed **six cell lines** for IFN responsiveness of USP18, UBA7, and UBCH8; UBA7 was “not discernible” in IFN-treated HCT116 cells until USP18 depletion. (pqac-00000017) | Clancy et al., 2023-07, https://doi.org/10.1042/bcj20230301 |
| Cellular localization / compartment | Direct localization data for UBA7 itself are limited in the retrieved 2023-2024 evidence. The pathway is clearly **intracellular**, and HERC5-mediated ISGylation is linked to **newly synthesized proteins**, consistent with major **cytosolic/ribosome-associated** activity, but the retrieved sources do **not provide a definitive UBA7 cytosol-vs-nucleus localization assignment**. (pqac-00000009, pqac-00000011, pqac-00000015, pqac-00000018) | Review, inference | Reviews distinguish **intracellular** versus **extracellular** ISG15, and HERC5 is associated with co-translational targeting of nascent proteins. Direct localization evidence for UBA7 remains limited in these sources. (pqac-00000011, pqac-00000015, pqac-00000018) | Sarkar et al., 2023-12, https://doi.org/10.1016/j.tim.2023.07.006; Álvarez et al., 2024-02, https://doi.org/10.3390/vaccines12020153 |
| Antiviral / innate immune application | UBA7 supports **antiviral innate immunity** by enabling ISGylation of immune and viral proteins. In a 2024 preprint, **UBA7 or ISG15 deficiency attenuated cGAS-STING downstream gene expression and antiviral activity**, and **UBA7 knockdown facilitated HSV-1 infection**. (pqac-00000016) | Cell, innate immunity | Human **cGAS** ISGylation sites reported: **K21, K187, K219, K458**. (pqac-00000016) | Chu et al., 2024-01, *bioRxiv*, https://doi.org/10.1101/2023.01.03.522548 |
| Viral restriction example | UBA7 is part of the machinery required for ISGylation of **SARS-CoV-2 nucleocapsid (N)** by **HERC5**, which impedes N oligomerization and viral RNA synthesis; viral **PLpro/NSP3** reverses this by deISGylation. (pqac-00000012) | Review, virology | N-protein ISGylation sites identified in the cited 2024 J Virol study: **K266, K355, K387, K388**. (pqac-00000012) | Zhu et al., 2024-09, *J Virol*, https://doi.org/10.1128/jvi.00869-24 |
| Recent primary study | **Afsar et al. 2023** established cryo-EM structures of human **Uba7** with **UBE2L6**, **ISG15 adenylate**, and **ISG15 thioester** intermediates, revealing the molecular basis for ISG15 activation and E1→E2 transfer. (pqac-00000006) | Structure, biochemistry | Structural complexes captured activation and transthiolation intermediates; article published **2023-08**. (pqac-00000006) | https://doi.org/10.1038/s41467-023-39780-z |
| Recent primary study | **Wallace et al. 2023** resolved a **3.45 Å cryo-EM** UBE1L–UBE2L6–activated ISG15 complex and dissected determinants of E1/E2 and ISG15/ubiquitin pathway specificity. (pqac-00000001, pqac-00000002) | Structure, biochemistry | Time-course charging assays used **0–900 s** intervals; article published **2023-12**. (pqac-00000001, pqac-00000002) | https://doi.org/10.1038/s41467-023-43711-3 |
| Recent primary study | **Madaan et al. 2024** used CRISPR disruption in fallopian tube epithelial cells and stated that **UBA7/UBE1L is the only ISG15-activating enzyme identified to date**, placing it at the first step of ISGylation. (pqac-00000018) | Cell | Published **2024-09**; functional context linked ISGylation to dsRNA-induced IFN and NF-κB signaling. (pqac-00000018) | https://doi.org/10.1016/j.jbc.2024.107686 |
| Recent primary study | **Zhu et al. 2024** showed HERC5-mediated ISGylation of **SARS-CoV-2 N** restricts viral RNA synthesis, illustrating a concrete antiviral output of the UBA7→UBE2L6→HERC5 axis. (pqac-00000012) | Cell, virology | N ISGylation sites: **K266, K355, K387, K388**; published **2024-09**. (pqac-00000012) | https://doi.org/10.1128/jvi.00869-24 |
| Recent primary study | **Chu et al. 2024** implicated UBA7 in **cGAS-STING** signaling: UBA7 deficiency or knockdown reduced antiviral gene induction and promoted **HSV-1** infection. (pqac-00000016) | Cell, innate immunity | Human cGAS lysine sites reported: **K21, K187, K219, K458**; published **2024-01** as preprint. (pqac-00000016) | https://doi.org/10.1101/2023.01.03.522548 |


*Table: This table summarizes verified functional annotation for human UBA7/UBE1L (UniProt P41226), including enzymatic mechanism, ISG15 specificity, pathway partners, regulation, and recent high-value studies. It is useful as a compact evidence map linking structural, biochemical, and cell-based findings to the ISGylation pathway.*